|
Hypercholesterolemia
|
0.900 |
Biomarker
|
disease |
BEFREE |
The History of the WHHL Rabbit, an Animal Model of Familial Hypercholesterolemia (II) - Contribution to the Development and Validation of the Therapeutics for Hypercholesterolemia and Atherosclerosis.
|
31748470 |
2020 |
|
Hypercholesterolemia
|
0.900 |
Biomarker
|
disease |
BEFREE |
The History of the WHHL Rabbit, an Animal Model of Familial Hypercholesterolemia (I) - Contribution to the Elucidation of the Pathophysiology of Human Hypercholesterolemia and Coronary Heart Disease.
|
31748469 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a genetic disorder caused by dysfunction of low density lipoprotein receptors (LDLr), resulting in elevated plasma cholesterol levels.
|
31815695 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Familial hypercholesterolaemia (FH) is caused by pathogenic variants in LDLR, APOB or PCSK9.
|
31833051 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is the most common genetic disorder of lipoprotein metabolism, affecting 1:250 individuals worldwide.
|
30318454 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Autosomal dominant familial hypercholesterolemia (FH) is caused by mutations in LDLR,APOB and PCSK9.
|
31809983 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a frequent genetic disorder characterized by elevated low-density lipoprotein (LDL)-cholesterol (LDL-C) levels and early onset of atherosclerotic cardiovascular disease.
|
31669498 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is an autosomal dominant disorder of lipoprotein metabolism that mainly occurs due to mutations in the low-density lipoprotein receptor gene and is characterized by increased levels of low-density lipoprotein cholesterol, leading to accelerated atherogenesis and premature coronary heart disease.
|
31633867 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
<b>Background:</b> Mutations in low-density lipoprotein receptor (<i>LDLR</i>) are one of the main causes of familial hypercholesterolemia (FH), which induces atherosclerosis and has a high lifetime risk of cardiovascular disease.
|
31779484 |
2020 |
|
Hypercholesterolemia, Familial
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to examine whether the c.2579C>T (p.A860V) variant of the LDLR gene affects the phenotype of FH.
|
30745271 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Autosomal dominant familial hypercholesterolemia (FH) is caused by mutations in LDLR,APOB and PCSK9.
|
31809983 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a genetic disorder caused by dysfunction of low density lipoprotein receptors (LDLr), resulting in elevated plasma cholesterol levels.
|
31815695 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a frequent genetic disorder characterized by elevated low-density lipoprotein (LDL)-cholesterol (LDL-C) levels and early onset of atherosclerotic cardiovascular disease.
|
31669498 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is the most common hereditary lipid disorder requiring life-long treatment to prevent cardiovascular disease.
|
31821958 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to examine whether the c.2579C>T (p.A860V) variant of the LDLR gene affects the phenotype of FH.
|
30745271 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is an autosomal dominant disorder of lipoprotein metabolism that mainly occurs due to mutations in the low-density lipoprotein receptor gene and is characterized by increased levels of low-density lipoprotein cholesterol, leading to accelerated atherogenesis and premature coronary heart disease.
|
31633867 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
<b>Background:</b> Mutations in low-density lipoprotein receptor (<i>LDLR</i>) are one of the main causes of familial hypercholesterolemia (FH), which induces atherosclerosis and has a high lifetime risk of cardiovascular disease.
|
31779484 |
2020 |
|
Hyperlipoproteinemia Type IIa
|
0.800 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is the most common genetic disorder of lipoprotein metabolism, affecting 1:250 individuals worldwide.
|
30318454 |
2020 |
|
Atherosclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
We studied the effects of inulin on lipid metabolism with a model of atherosclerosis in LDL receptor-deficient mice using lipidomics and transcriptomics.
|
31604806 |
2020 |
|
Atherosclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
We generated myeloid cell-specific Ncor1 knockout mice and crossbred them with low-density lipoprotein receptor (Ldlr) knockouts to study the role of macrophage NCOR1 in atherosclerosis.
|
31529020 |
2020 |
|
Atherosclerosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The History of the WHHL Rabbit, an Animal Model of Familial Hypercholesterolemia (II) - Contribution to the Development and Validation of the Therapeutics for Hypercholesterolemia and Atherosclerosis.
|
31748470 |
2020 |
|
Atherosclerosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a frequent genetic disorder characterized by elevated low-density lipoprotein (LDL)-cholesterol (LDL-C) levels and early onset of atherosclerotic cardiovascular disease.
|
31669498 |
2020 |
|
Atherosclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, pharmacological inhibition of ACLY by bempedoic acid, prevents dyslipidemia and attenuates atherosclerosis in hypercholesterolemic ApoE<sup>-/-</sup> mice, LDLr<sup>-/-</sup> mice, and LDLr<sup>-/-</sup> miniature pigs.
|
31499095 |
2020 |
|
Atherosclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Impaired low-density lipoprotein (LDL) receptor function leads to decreased LDL catabolism and premature atherosclerotic cardiovascular disease (ASCVD).
|
31833051 |
2020 |
|
Atherosclerosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study demonstrates that combination of MEK1/2 inhibitor and LXR ligand can synergistically reduce atherosclerosis in LDLR deficient mice without lipogenic side effects.
|
31784089 |
2020 |